Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 418752, 16 pages
Research Article

Comparative Analysis of the Hematopoietic Progenitor Cells from Placenta, Cord Blood, and Fetal Liver, Based on Their Immunophenotype

1Institute of Cell Therapy, Komarova Avenue 3, Kyiv 03680, Ukraine
2Institute of Molecular Biology and Genetics, National Academy of Sciences of Ukraine, Zabolotnogo Street 150, Kyiv 03680, Ukraine
3State Institute of Genetics and Regenerative Medicine, National Academy of Medical Sciences of Ukraine, Vyshgorodska Street 67, Kyiv 04114, Ukraine

Received 10 April 2015; Revised 3 July 2015; Accepted 8 July 2015

Academic Editor: Dimitra Gkika

Copyright © 2015 Maria D. Kuchma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We have investigated the characteristics of human hematopoietic progenitor cells (HPCs) with the CD34+CD45lowSSClow phenotype from full-term placental tissue (FTPT) as compared to cord blood (CB) and fetal liver (FL) cells. We demonstrated the presence of cell subpopulations at various stages of the differentiation with such immunophenotypes as CD34+/low, CD34++, CD34+++, CD45hi, and CD34++CD45hi in both first trimester placental tissue (FiTPT) and FTPT which implies their higher phenotypic heterogeneity compared to CB. HPCs of the FTPT origin expressed the CD90 antigen at a higher level compared to its expression by the CB HPCs and the CD133 antigen expression being at the same level in both cases. The HPCs compartment of FTPT versus CB contained higher number of myeloid and erythroid committed cells but lower number of myeloid and lymphoid ones compared to FL HPCs. HPCs of the FTPT and CB origin possess similar potentials for the multilineage differentiation in vitro and similar ratios of myeloid and erythroid progenitors among the committed cells. This observation suggests that the active hematopoiesis occurs in the FTPT. We obtained viable HPCs from cryopreserved placental tissue fragments allowing us to develop procedures for banking and testing of placenta-derived HPCs for clinical use.